Search research articles
Contact Us
Filters
Showing results (301-310 of 324) with videos related to
Page
of 33
Sort By:
JCO Clinical Cancer Informatics
|
May 1, 2026
Interpreting Treatment Effects Using Posterior Probabilities: A Bayesian Reanalysis of 230 Phase III Oncology Trials
Alexander D Sherry, Pavlos Msaouel, Gabrielle S Kupferman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 12, 2024
Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation
Timothy A Lin, Zachary R McCaw, Alex Koong, et al.
Arthritis and Rheumatism
|
July 1, 2009
Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis
Michael G Barnes, Alexei A Grom, Susan D Thompson, et al.
European Urology
|
April 28, 2026
Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials
Alexander D Sherry, Van To, Criselle D'souza, et al.
Cancer Research Communications
|
August 5, 2024
Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Esther J Beck, Alexander D Sherry, Marcus A Florez, et al.
Journal of the National Cancer Institute
|
February 8, 2024
Association of differential censoring with survival and suboptimal control arms among oncology clinical trials
Eric J Hsu, Timothy A Lin, Dor R Dabush, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
May 20, 2014
Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis
Norman T Ilowite, Kristi Prather, Yuliya Lokhnygina, et al.
European Urology
|
March 1, 2026
KIM-1 and Circulating Tumor DNA Are Prognostic Markers for Oligometastatic Clear-cell Renal Cell Carcinoma: Development of a Multivariable Prognostic Model
Chad Tang, Aaron Seo, Alexander D Sherry, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 1, 2024
Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase 2 Trial
Jay P Reddy, Alexander D Sherry, Bryan Fellman, et al.
The Lancet. Oncology
|
February 5, 2026
Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration
Chad Tang, Alex D Sherry, Hyunsoo Hwang, et al.
Page
of 33
Search research articles
Search
Showing results (301-310 of 324) with videos related to
Sort By:
Page
of 33
JCO Clinical Cancer Informatics
|
May 1, 2026
Interpreting Treatment Effects Using Posterior Probabilities: A Bayesian Reanalysis of 230 Phase III Oncology Trials
Alexander D Sherry, Pavlos Msaouel, Gabrielle S Kupferman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 12, 2024
Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation
Timothy A Lin, Zachary R McCaw, Alex Koong, et al.
Arthritis and Rheumatism
|
July 1, 2009
Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis
Michael G Barnes, Alexei A Grom, Susan D Thompson, et al.
European Urology
|
April 28, 2026
Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials
Alexander D Sherry, Van To, Criselle D'souza, et al.
Cancer Research Communications
|
August 5, 2024
Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Esther J Beck, Alexander D Sherry, Marcus A Florez, et al.
Journal of the National Cancer Institute
|
February 8, 2024
Association of differential censoring with survival and suboptimal control arms among oncology clinical trials
Eric J Hsu, Timothy A Lin, Dor R Dabush, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
May 20, 2014
Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis
Norman T Ilowite, Kristi Prather, Yuliya Lokhnygina, et al.
European Urology
|
March 1, 2026
KIM-1 and Circulating Tumor DNA Are Prognostic Markers for Oligometastatic Clear-cell Renal Cell Carcinoma: Development of a Multivariable Prognostic Model
Chad Tang, Aaron Seo, Alexander D Sherry, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 1, 2024
Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase 2 Trial
Jay P Reddy, Alexander D Sherry, Bryan Fellman, et al.
The Lancet. Oncology
|
February 5, 2026
Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration
Chad Tang, Alex D Sherry, Hyunsoo Hwang, et al.
Page
of 33